Global Pain Management Market Report: 2015 Edition


#494664

55pages

Koncept Analytics

$ 800

In Stock

Pain is defined as an unpleasant feeling brought on by a noxious stimuli or injury. The expression of pain can drive someone to stay away from harmful situations, defend injured tissues and avoid similar situations in future. Usually pain is classified as either acute or chronic, and can also be classified into mild, moderate and severe on the basis of severity of pain. The most common types of pain include back pain, orthopedic pain, cancer pain, post-surgical pain and neuropathic pain. Acute pain lasts for shorter duration and gradually resolves as the injured tissue heals but chronic pain lasts longer than 12 weeks and persists even after complete tissue healing.

Increasing incidences of chronic pain conditions globally, increasing recognition of the benefits relating to pain management by the physicians and patients, introduction of innovative drugs for pain treatment, escalating diabetic and obese population, increasing women

Table of Content

1. Overview
1.1 Definition of Pain    
1.2 Classification of Pain with Pathophysiology
1.2.1 Acute Pain    
1.2.2 Chronic Pain
1.3 Categories of Pain by Indications
1.3.1 Neuropathic Pain    
1.3.2 Post-Operative Pain
1.4 Treatment Options for Pain
1.4.1 Chronic Pain    
1.4.2 Neuropathic Pain    
1.4.3 Post-Operative Pain
1.5 Opioids Overview
1.5.1 Opioids and Opioid Receptors    
1.5.2 Opioid Dependence    
1.5.3 Treatment Options for Opioid Dependency

2. Pain Management Market Analysis

  • Global Market Value
  • Global Market Segmentation
  • US Prescription Pain Management Market

2.1 Chronic Pain Management Market

  • Global Sales of Branded Narcotics
  • Market Share by Drug Classes
  • Global Opioids Market Value

2.2 Neuropathic Pain Management Market

  • Global Market Value
  • Market Share by Drug Classes

2.2.1 Diabetic Neuropathic Pain Market
2.3 Post-Operative Pain Management Market
2.3.1 The U.S. Post-Operative Market    

  • Market Value & Volume
  • Market Share by Drug Classes

3. Opioid Dependence Market
3.1 The U.S. Opioid Dependence Market

  • Prevalence of Opioid Use
  • Sales of Branded Products
  • Buprenorphine Market Value

4. Market Dynamics
4.1 Key Trends and Developments
4.1.1 Abuse-Deterrent Drugs under Development for Chronic Pain    
4.1.2 Pain Relieving Devices as the Fastest Growing Healthcare Category    
4.1.3 Rising Opportunity for Buprenorphine Based Drugs    
4.1.4 Variation in Demand for Opioid Treatments by Region    
4.1.5 Untapped Local Anesthetics Market for Post-operative Pain    
4.1.6 Pain Management Drugs in Latest Stage of Development    
4.1.7 Substantial Impact of Chronic Pain in the U.S.    
4.1.8 Several Certified Physicians for Pain Management in the U.S.
4.2 Growth Drivers
4.2.1 Escalating Diabetic Population Worldwide    
4.2.2 Burgeoning Obese Population    
4.2.3 Increasing Population of Women    
4.2.4 Global Spending on Medicines    
4.2.5 Growing Ageing Population    
4.2.6 Rising Healthcare Expenditure
4.3 Challenges
4.3.1 Limitations of Intravenous NSAIDs
4.3.2 Increasing Death Incidents from Opioids Consumption    
4.3.3 Increasing Threat from Generic Introduction

5. Competitive Landscape
5.1 Global Market    
5.2 The U.S. Market

6. Company Profiles
6.1 Endo International Plc.
6.1.1 Business Overview    
6.1.2 Financial Overview    
6.1.3 Business Strategies
6.2 AstraZeneca
6.2.1 Business Overview    
6.2.2 Financial Overview    
6.2.3 Business Strategies
6.3 Johnson & Johnson
6.3.1 Business Overview    
6.3.2 Financial Overview    
6.3.3 Business Strategies
6.4 Pfizer, Inc.
6.4.1 Business Overview    
6.4.2 Financial Overview    
6.4.3 Business Strategies 

Pain Treatment Matrix
Approved Pharmacological Treatment Drugs for Chronic Pain
Approved and Late-Stage Drugs for Neuropathic Pain
Current Drug Classes used for Post-Operative Pain
Currently Approved Treatment Options for Opioid Dependence
Global Sales of Branded Long-Acting Narcotics (2011-2014)
Global Sales of Approved Drugs for Diabetic Neuropathic Pain (2012-2014)
The U.S. Sales of Branded Approved Buprenorphine/Naloxone Products (2014)
Drugs under Development for Severe Chronic Pain 
Pain Management Drugs in/after Third Phase Development
Generic Entrances in Long-Acting Narcotics Drugs  

Classification of Pain by Type
Global Pain Management Market Value (2009-2014)
Global Pain Prescription Drugs Market Share by Indication (2014)
The U.S. Prescription Pain Market Share by Drug Type (2014)
The U.S. Prescription Pain Market Share by Product Value (2014)
The U.S. Prescription Pain Market Share by Product Volume (2014)
Global Chronic Pain Market Share by Drug Classes (2014)
Global Opioids Prevalence of Use (2010-2013)
Global Opioids Market Value (2010-2017E)
Neuropathic Pain Market Value (2010-2014)
Neuropathic Pain Market Share by Drug Classes (2014)
The U.S. Post-Operative Pain Market Value & Volume of Surgical Procedures (2012-2022E)
The U.S. Post-Operative Pain Market Share by Drug Classes (2014)
The U.S. Prevalence of Opioid Use (2014)
The U.S. Buprenorphine Market Value (2008-2014)
Growth in Healthcare Categories in the U.S. (2014)
Percentage of First Time Users of Opioid Treatment by Region (2014)
Local Anesthetics Market Opportunity for Post-Operative Pain (2014)
Population Affected by Chronic Diseases in the U.S. 
Proportion of Certified & Non-Certified Pain Management Physicians in the U.S
Global Diabetic Population by Region (2013-2023E)
Global Obese Population (2009-2014)
Global Female Population, Over 45 Years (2008-2014)
Global Spending on Medicines (2010-2020E)
Global Ageing Population Over 65 (2009-2014E)
Global Healthcare Expenditure Per Capita (2009-2014E)
Deaths Related to Opioid Painkillers in the U.S. (2000-2013)
Global Prescription Drugs Pain Management Market Share by Company (2014)
Global Prescription Drugs Pain Management Market Share by Company (2019E)
The U.S. Buprenorphine/Naloxone Market Share by Products (2014)
Endo International Plc Revenue by Segment (2013/2014)
Endo International Plc Revenue (2010-2014)
AstraZeneca Revenue by Therapeutic Segment (2013/2014)
AstraZeneca Revenue by Regions (2013/2014)
AstraZeneca Revenue and Net profit (2010-2014)
AstraZeneca Pipeline Development Projects (2012-2014)
Johnson & Johnson Revenue by Business Segments (2014)
Johnson & Johnson’s Revenue and Net Income (2010-2014)
Pfizer’s Sales by Business Segments (2014)
Pfizer’s Sales & Net Income (2010-2014)